What the FDA labels say about taking them together
Adalimumab and azathioprine
Adalimumab's FDA label of October 21, 2025 names azathioprine in its boxed warning section; the azathioprine label PlainMeds reads does not name adalimumab. The adalimumab label: “The potential risk with the combination of azathioprine or 6-mercaptopurine and HUMIRA should be carefully considered.”
Check it at the source: the adalimumab FDA label on DailyMed (effective October 21, 2025); the azathioprine FDA label on DailyMed (effective November 8, 2025, Sebela Pharmaceuticals Inc.).
What does the adalimumab label say about azathioprine?
Adalimumab label, boxed warningAlmost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis.
Adalimumab label, warnings and precautionsThe potential risk with the combination of azathioprine or 6-mercaptopurine and Adalimumab-adaz should be carefully considered.
Source: FDA drug label (Humira, BLA125057), AbbVie Inc., effective December 23, 2025 (SPL set 608d4f0d-b19f-46d3-749a-7159aa5f933d), via openFDA
Source: FDA drug label (Adalimumab-Aacf, BLA761255), Fresenius Kabi USA, LLC, effective January 8, 2026 (SPL set 2488b0bc-7b8f-4cc8-91ea-48e7ea5e8915), via openFDA
Source: FDA drug label (Adalimumab), Sandoz Inc, effective October 21, 2025 (SPL set 3468792f-63ef-4916-8ed1-8214f327d9dd), via openFDA; the full label on DailyMed
What does the azathioprine label say about adalimumab?
Azathioprine's label (effective November 8, 2025) does not name adalimumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (IMURAN), NDA016324 (Legacy), as published by Sebela Pharmaceuticals Inc., effective November 8, 2025 (SPL set 606101a0-6244-7eff-e053-2a91aa0acadd), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Adalimumab | Azathioprine | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | Organ transplant rejection, Rheumatoid arthritis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1,587.82 per mL 40 mg/0.4 mL | $0.124 per tablet 50 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once